U.S. FDA Approves Kite’s Tecartus® as the First and Only CAR T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
October 6, 2021, 4:41 pm
U.S. FDA Approves Kite’s Tecartus® as the First and Only CAR T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia -- 65% of Patients Achieved Overall Complete Remission with Tecartus -- -- High Unmet Need: Fifty Percent of Adult Patients Will Relapse
